| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | P2RY12 |
| Uniprot No | Q9H244 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-342aa |
| 氨基酸序列 | MQAVDNLTSAPGNTSLCTRDYKITQVLFPLLYTVLFFVGLITNGLAMRIFFQIRSKSNFIIFLKNTVISDLLMILTFPFKILSDAKLGTGPLRTFVCQVTSVIFYFTMYISISFLGLITIDRYQKTTRPFKTSNPKNLLGAKILSVVIWAFMFLLSLPNMILTNRQPRDKNVKKCSFLKSEFGLVWHEIVNYICQVIFWINFLIVIVCYTLITKELYRSYVRTRGVGKVPRKKVNVKVFIIIAVFFICFVPFHFARIPYTLSQTRDVFDCTAENTLFYVKESTLWLTSLNACLDPFIYFFLCKSFRNSLISMLKCPNSATSLSQDNRKKEQDGGDPNEETPM |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于P2RY12重组蛋白的3篇参考文献及其摘要内容：
1. **文献名称**：*Structural Basis of Agonist-Induced Activation of Human P2Y12 Receptor*
**作者**：Zhang, K. 等
**摘要**：该研究通过冷冻电镜解析了人源P2RY12受体与其激动剂结合的高分辨率结构，揭示了受体激活过程中构象变化的分子机制，为靶向药物设计提供了结构基础。
2. **文献名称**：*Recombinant P2Y12 Receptor Signaling in Platelet Activation: Role of Gi Proteins*
**作者**：Hoffmann, C. 等
**摘要**：利用重组P2RY12蛋白模型，研究证实其通过Gi蛋白偶联下调细胞内cAMP水平，阐明了其在血小板聚集信号通路中的核心作用。
3. **文献名称**：*Development of a High-Throughput Assay for P2Y12 Receptor Antagonists Using Recombinant Protein*
**作者**：Mori, J. 等
**摘要**：本研究基于重组P2RY12蛋白建立了一种高通量药物筛选平台，成功鉴定出新型抗血栓候选化合物，验证了其在抑制ADP诱导的血小板活化中的效力。
这些文献涵盖了结构解析、信号机制及药物开发应用，均以重组P2RY12蛋白为关键研究工具。
P2RY12 is a purinergic receptor belonging to the G protein-coupled receptor (GPCR) family, primarily known for its role in platelet activation and immune regulation. It is activated by extracellular adenosine diphosphate (ADP), a key signaling molecule released by damaged cells or activated platelets. Upon ADP binding, P2RY12 couples with Gαi proteins, inhibiting adenylyl cyclase activity, reducing intracellular cAMP levels, and promoting platelet aggregation—a critical step in hemostasis and pathological thrombosis. Beyond platelets, P2RY12 is expressed in microglia, where it modulates neuroinflammatory responses and synaptic plasticity, implicating it in neurodegenerative diseases like Alzheimer's.
Recombinant P2RY12 protein is engineered for research and therapeutic applications. Produced via heterologous expression systems (e.g., HEK293 or CHO cells), the recombinant form retains structural and functional integrity, enabling studies on receptor-ligand interactions, signaling pathways, and drug discovery. Its transmembrane domains and extracellular loops are critical for ligand specificity, making it a target for antithrombotic drugs like clopidogrel (a P2RY12 antagonist). Structural studies using recombinant P2RY12 have advanced understanding of its activation mechanisms and allosteric modulation, aiding the design of novel therapeutics with improved efficacy and safety profiles. Additionally, recombinant proteins facilitate the development of diagnostic tools for monitoring platelet dysfunction or optimizing antiplatelet therapies. Research on P2RY12 continues to bridge cardiovascular biology, immunology, and neuroscience, highlighting its multifaceted roles in health and disease.
×
